You may have a point. My course of action depends on our data showing efficacy. I believe that the DSMC would not have recommended continuing the trial if results were negative. I also see their suggestion of continuing only to 293 before another interim analysis as meaning Leronlimab is effective but maybe not with enuf statistical patients. I see the playing field not being level at the FDA. As I said Dr NP should discuss with MHRA and the Philippines, the DSMC recommendation, the eINDs, and hear their reaction and how they would proceed if we had borderline results. He could then decide on next action. So, no at this point, there is zero risk just exploring options with an open mind.